Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-Controlled, Cross-Over Trial of Aripiprazole

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Age 18-65~* Diagnosis of schizophrenia, any subtype, or schizoaffective disorder, any sub-type~* Body mass index \> 30 Kg/m2 or \>27 Kg/m2 with other risk factors (HTN, Lipid abnormalities)~* Well established compliance with outpatient medications.~* Maintained on a stable dose of olanzapine for at least one month.~Exclusion Criteria:~* Serious medical or neurological illness (unstable cardiac disease, malignancy, liver or renal impairment, etc.)~* Current substance abuse~* Psychiatrically unstable, which is defined as a score on the CGI's severity of illness question of 5 or greater or a baseline Total PANSS score \> 75~* Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile~* Serious suicidal or homicidal risk within the past three months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Aripiprazole (Type: ACTIVE_COMPARATOR): aripiprazole 15mg/day
- placebo (Type: PLACEBO_COMPARATOR): matched placebo for aripiprazole 15mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).